Reduced bacterial adhesion to fibrinogen-coated substrates via nitric oxide release by Charville, Gregory W. et al.
Reduced bacterial adhesion to fibrinogen-coated substrates via
nitric oxide release
Gregory W. Charville†, Evan M. Hetrick†, Carri B. Geer, and Mark H. Schoenfisch*
Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3290
Abstract
The ability of nitric oxide (NO)-releasing xerogels to reduce fibrinogen-mediated adhesion of
Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli is described. A negative
correlation was observed between NO surface flux and bacterial adhesion for each species tested.
For S. aureus and E. coli, reduced adhesion correlated directly with NO flux from 0 to 30 pmol
cm−2 s−1. A similar dependence for S. epidermidis was evident from 18 to 30 pmol cm−2 s−1. At a
NO flux of 30 pmol cm−2 s−1, surface coverage of S. aureus, S. epidermidis, and E. coli was reduced
by 96, 48, and 88%, respectively, compared to non-NO-releasing controls. Polymeric NO release
was thus demonstrated to be an effective approach for significantly reducing fibrinogen-mediated
adhesion of both gram-positive and gram-negative bacteria in vitro, thereby illustrating the advantage
of active NO release as a strategy for inhibiting bacterial adhesion in the presence of pre-adsorbed
protein.
Introduction
From orthopedic prostheses to ventricular shunts, modern medical procedures increasingly rely
on indwelling devices, many of which reside within the body for extended periods.
Unfortunately, infections associated with indwelling medical devices remain a significant
clinical challenge [1]. For example, the number of catheter-related bloodstream infections
yearly in the U.S. has been estimated at >500,000 [1]. Such infections have a mortality rate of
up to 25%; treatment costs alone approach roughly $28,000 per case [2,3]. Altogether,
infections associated with indwelling devices account for nearly half of the two million
nosocomial infections that occur in the U.S. each year [4].
Infection of indwelling devices initiated by bacteria occurs in three phases [5]. Immediately
after insertion, plasma proteins rapidly coat the surface of the device. The initial interaction
between bacterial cells and the adsorbed protein layer is non-specific through a combination
of van der Waals, gravitational, and Coulombic forces [6]. During Phase II, bacterial membrane
proteins and polysaccharides specifically bind to the proteins on the device surface. Certain
bacterial species subsequently secrete a protective exopolysaccharide layer (i.e.,form a biofilm)
in Phase III that imparts increased antibiotic resistance to the constituent bacterial cells [7].
Biofilm-associated bacterial infections are exceedingly difficult to treat with conventional
antibiotic therapies. Thus, the most promising anti-infective strategies seek to inhibit bacterial
adhesion prior to biofilm formation. Reducing bacterial adhesion during the initial 6 h period
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following implantation is particularly important for avoiding device-associated infection [8].
Indeed, the risk of infection is significantly decreased if the implant is properly integrated into
the surrounding tissue prior to colonization of the surface by bacteria.
To combat implant-associated infection, much research has focused on device coatings that
reduce initial bacterial adhesion [9]. Passive device coatings have been developed that possess
physicochemical properties such that bacteria-substrate interactions become less favorable
[9]. While such coatings have shown promise at reducing bacterial adhesion in vitro, their
efficacy in vivo has been hindered by the adsorption of plasma proteins that mask the
physicochemical properties of the underlying substrate. In contrast, coatings that actively
release antimicrobial agents have been shown to reduce bacterial adhesion even in the presence
of a surface-adsorbed protein layer [10]. Examples of active release coatings include polymers
that release antibodies that block adhesins on the bacterial cell surface [11], silver ions [12],
and conventional antibiotics [13]. Unfortunately, the highly selective nature of antibodies and
increasing microbial resistance to silver ion [14] and antibiotics [15] warrant research into more
effective active release strategies to prevent bacterial adhesion and associated infection.
Polymeric nitric oxide (NO) release has recently been proposed as a strategy to prevent bacterial
adhesion and device-associated infection [9]. Relative to traditional antibiotics (e.g.,
gentamicin, cephalothin, etc.), NO has a short half-life in both blood and tissue (on the order
of seconds) [16], allowing localized action without systemic effects common to some
conventional antibiotics [17]. Nitric oxide is an appealing means of inhibiting bacterial
adhesion because it is capable of functionally modifying key bacterial cell membrane adhesin
proteins that mediate cell-substrate interactions [18]. In addition, NO has been observed to
induce the dispersal of bacteria in biofilms, suggesting an antagonistic role in biofilm
development [19]. The primary mechanisms by which NO exhibits bactericidal activity include
membrane destruction via lipid peroxidation by NO-derived peroxynitrite (ONOO−) [20],
irreparable DNA damage [21], and the inhibition of critical metalloproteins found in bacterial
respiratory reactions [22]. Whereas the effectiveness of traditional antibiotics is often
undermined by the evolution of resistant bacteria, the more general nature of NO-induced cell
death may limit similar development of bacterial resistance to NO [23].
Xerogel polymers modified to release NO have emerged as a class of materials capable of
inhibiting bacterial adhesion [24]. While several studies have demonstrated the ability of
xerogel-derived NO to reduce bacterial adhesion in vitro [25–28] and limit implant-associated
infection in vivo [29], the ability of polymeric NO release to prevent bacterial adhesion in the
presence of an adhesion-promoting protein layer has not yet been investigated. Herein, we
examine the efficacy of NO release as a strategy to reduce the protein-mediated adhesion of
Staphylococcus aureus, Staphylococcus epidermidis, and Eschericia coli, bacterial species that
are collectively responsible for a significant portion of medical device-related infections and
whose adhesion to biomaterial substrates is mediated by fibrinogen (Fg) and other plasma
proteins [30–33]. By examining the extent of adhesion of S. aureus, S. epidermidis, and E.
coli to Fg-coated NO-releasing xerogels, the efficacy of NO-release as a strategy to reduce
protein-mediated bacterial adhesion is explored.
Materials and Methods
Reagents
Water was purified to a resistivity of 18.2 MΩ·cm and total organic content of <5 ppb using a
Millipore Milli-Q Gradient A-10 water purification system (Bedford, MA).
Isobutyltrimethoxysilane (BTMOS) was purchased from Aldrich (St. Louis, MO). N-(6-
Aminohexyl)-aminopropyltrimethoxysilane (AHAP3) was purchased from Gelest
(Morrisville, PA). Silanes were stored under nitrogen and used as received. Argon (Ar),
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nitrogen (N2), and nitric oxide (NO) gases were purchased from National Welders (Raleigh,
NC). Low molecular weight poly(vinyl chloride) (PVC) and tetrahydrofuran (THF) were
purchased from Aldrich. Staphylococcus aureus (ATCC #29213), Staphylococcus
epidermidis (ATCC #12228), and Escherichia coli (ATCC #11775) were purchased from
American Type Culture Collection. Human fibrinogen (plasminogen depleted; Lot FIB 1 2800;
100% clottable) was purchased from Enzyme Research Laboratories (South Bend, IN) at a
concentration of 45.76 mg/mL in 20 mM sodium citrate-HCl buffer (pH 7.4), and stored at
−80 °C. Bovine serum albumin (BSA) was purchased from Sigma (St. Louis, MO).
Tetrahydrofuran (THF) and all other chemicals were purchased from Fisher Scientific (St.
Louis, MO) and used as received.
AHAP3 xerogel synthesis
Xerogels were prepared as described previously [28] by mixing 800 µL of a volume percent
mixture of BTMOS and AHAP3 with 800 µL of ethanol (EtOH), 240 µL of H2O, and 40 µL
of 0.5 M hydrochloric acid (HCl). Synthesis of the xerogel polymers was carried out in two
steps. First, EtOH, H2O, HCl, and BTMOS were mixed for 1 h. AHAP3 was then added to this
solution, followed by additional mixing for 1 h. Glass microscope slides were cut into 25 mm
× 8 mm sections, sonicated in EtOH for 20 min, dried with N2 gas, and ozone-cleaned for 30
min in a BioForce UV-cleaner (Ames, IA) before use. A 35-µL aliquot of the sol was cast onto
each glass slide. The films were allowed to solidify (i.e., gel) in a fume hood for 15 min, and
then dried in an 80 °C oven for 72 h. The resulting xerogels were stored in a desiccator at 25
°C prior to further study.
Nitric oxide donor formation
Diazeniumdiolate-modified xerogels were synthesized by placing the xerogel-coated glass
slides into a 500-mL in-house NO reaction vessel [24]. Before exposure to NO, the reaction
chamber was flushed with Ar (5 atm) to remove O2. The reactor was then pressurized to 5 atm
NO for 72 h. After 72 h, NO was removed from the reaction chamber via copious flushing with
Ar. The NO donor-modified xerogels were stored at −20 °C under N2 until use to limit both
thermal- and water vapor-initiated diazeniumdiolate decomposition [24]. Control xerogels, not
modified with diazeniumdiolate NO-donors, were stored in a desiccator at ambient
temperature.
Poly(vinyl chloride) coating
Low molecular weight poly(vinyl chloride) (1.0 g) was dissolved in THF (10 mL). Precisely
300 µL of the PVC/THF solution was spin-coated onto control and NO-releasing xerogels
using a CHEMAT Technology KW-4A Precision Spin-Coater (Northridge, CA) set to spin at
3.0 krpm. The PVC-coated xerogels were immediately dried with N2 and returned to −20 °C
until further study. The approximate thickness of the PVC overlayer was measured using a
Zeiss Axiovert 200 Inverted Optical Microscope (Chester, VA).
Characterization of nitric oxide release
A chemiluminescent nitric oxide analyzer (NOA; Sievers Model 280; Boulder, CO) was used
to quantify NO release from the PVC-coated diazeniumdiolate-modified xerogels. The
xerogel-coated glass substrates were placed in a vessel containing deoxygenated phosphate-
buffered saline (PBS, pH 7.4) maintained at 37 °C using a heated water bath. The PBS vessel
was purged continuously with N2 gas. The NOA was calibrated with an atmospheric sample
passed through a NO zero filter (0 ppm) and a NO gas standard (24.1 ppm; balance N2).
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Bacteria were cultured in tryptic soy broth (TSB) at 37 °C, pelleted by centrifugation, rinsed
with H2O, resuspended in a solution of PBS with 15% (v:v) glycerol, and stored at −80 °C.
From the −80 °C stock, secondary cultures were grown in TSB for ~12 h. A 1 mL portion of
the mature colony was inoculated into 200 mL of TSB and grown to approximately 108 colony-
forming-units (CFU) per mL. Bacterial cell concentrations were measured by optical density
(ODλ=600 nm ≈ 0.2 for S. aureus and S. epidermidis; ODλ=600 nm ≈ 0.5 for E. coli). The resulting
culture was collected by centrifugation and resuspended in PBS. Serial dilutions and plating
of the resuspended bacteria on tryptic soy agar verified that the concentration of viable cells
was consistent between experiments.
The PVC-coated NO-releasing and control xerogels were soaked in PBS for 90 min at 37 °C
to initiate a steady level of NO release. The xerogels were immediately incubated with gentle
shaking in 5 mL of a 20 µg/mL solution of either human Fg or BSA in PBS (pH 7.4) for 90
min at 37 °C. After removal from the protein solution, the xerogels were immersed in 5 mL of
a bacterial suspension at 37 °C for 90 min with gentle shaking.
Phase contrast microscopy
Following incubation in the bacterial suspension, the xerogels were removed, rinsed by gently
immersing the slides in H2O to remove loosely adhered bacteria, and then dried with a stream
of N2. Adhered bacteria were imaged via phase contrast optical microscopy using a Zeiss
Axiovert 200 Inverted Microscope equipped with a Zeiss Axiocam. For each xerogel
composition (i.e., NO flux), three different xerogel-coated slides with PVC overlayers were
imaged. Five randomly-selected regions (215 × 270 µm2) on each slide were used to calculate
an average bacterial surface coverage. The images were digitally processed by thresholding to
make white cells contrast sharply with the dark background. Percent surface coverage was
translated from the number of white versus black pixels in the thresholded image and
normalized relative to controls (scored as 1.0).
Water contact angle measurements
Static water contact angle measurements of both untreated and protein-treated (20 µg/mL Fg
or BSA in PBS, pH 7.4 for 90 min) PVC-coated control xerogels were acquired with a KSV
Instruments Cam 200 Optical Contact Angle Meter (Helsinki, Finland).
Fibrinogen surface coverage measurements
To determine the relative amount of Fg adhered to both control and NO-releasing substrates,
Fg was fluorescently labeled [34] using an Alexa Fluor 488 Protein Labeling Kit (Invitrogen;
Eugene, OR) per the manufacturer’s instructions [35]. A volume of 500 µL of a protein solution
prepared by mixing 10% fluorescently-tagged Fg and 90% unlabeled Fg (20 µg/mL total Fg
concentration) was deposited on both control and NO-releasing PVC-coated 40% AHAP3/
BTMOS xerogels (n = 3 of each) that had been previously immersed in PBS for 90 min at 37
°C. After 90 min at 37 °C, the substrates were removed from the Fg solution and gently rinsed
with PBS to remove loosely adhered protein. Adsorbed Fg was then eluted by immersing the
slides in a 5% solution of sodium dodecyl sulfate (SDS) [36] in PBS at 37 °C for 90 min. The
fluorescence intensity of the SDS/PBS solution was monitored with a Varian/Cary Eclipse
Spectrofluorometer (Palo Alto, CA). An excitation wavelength of 495 nm was employed, and
fluorescence emission was monitored from 515 to 525 nm [35].
Statistical analysis
All data are expressed as mean values ± one standard deviation and were analyzed for
significance (p < 0.05) with a two-tailed Student’s t-test.
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Poly(vinyl chloride)-coated xerogel characteristics
A spin-coated PVC overlayer was used to ensure surface uniformity of xerogel samples
composed of different proportions of aminosilane (i.e., AHAP3) and alkoxysilane backbone
(i.e., BTMOS). As such, differences in bacterial adhesion may be attributed solely to NO
release and not other potentially significant changes in substrate surface properties. Our lab
has previously reported the benefits of a polymer overcoat for enhancing the stability of
aminosiliconalkoxide-modified xerogels upon immersion in aqueous solution [28]. For the
xerogel substrates described herein, neither delamination nor degradation of either the PVC or
xerogel film was observed. As measured by optical microscopy, the average thickness of the
PVC layer was 15 ± 4 µm.
Nitric oxide release
Xerogels enable careful study of the effects of NO release on bacterial adhesion because the
NO flux from such materials is readily tunable by altering the identity and/or concentration of
the aminosilane precursor [24]. The AHAP3/BTMOS xerogel composition was selected based
on the superior solution stability of the ensuing xerogel film compared to other combinations
of amino- and alkoxysilanes. By tuning the amount of AHAP3 relative to BTMOS during
xerogel synthesis, this system also provides a range of constant NO fluxes (10–30 pmol
cm−2 s−1) over which to study bacterial adhesion.
To prepare substrates with a range of NO surface fluxes, xerogels composed of 10–40%
AHAP3 were synthesized, modified to diazeniumdiolate NO donor form, and coated with a
PVC overlayer. As shown in Figure 1, increasing the proportion of AHAP3 resulted in a greater
NO surface flux, thus enabling the investigation of the relationship between NO flux and
bacterial adhesion. The NO release profiles during the 90 min period from 3 to 4.5 h following
xerogel immersion in PBS buffer are depicted in the inset of Figure 1. This period represents
the incubation time during which the bacterial adhesion experiments were performed. The
average NO flux of each of the four xerogel samples fell within 10 to 30 pmol cm−2 s−1, levels
of NO previously reported to significantly reduce P. aeruginosa adhesion [28]. Of note, the
NO flux for each of the four xerogels remained constant throughout the 90-min bacterial
adhesion assay, with 10, 20, 30, and 40% AHAP3 xerogels generating an average NO flux of
approximately 11, 18, 23, and 30 pmol cm−2 s−1, respectively, during the 3 to 4.5 h period after
PBS immersion.
Fibrinogen-mediated bacterial adhesion
The pervasiveness of Fg as a mediator of bacterial adhesion [31–33] makes it appealing to
include in studies aimed at elucidating the influence of polymeric NO release on protein-
mediated bacterial adhesion. Fibrinogen promotes bacterial adhesion by bridging the
biomaterial surface with bacterial cell membrane receptors specific to Fg [37]. Such
interactions are responsible for bacterial adhesion to medical devices in vivo, and bacteria
possessing the ability to specifically bind surface-adsorbed Fg have been found to be
responsible for significantly more clinical orthopedic and cardiovascular device-associated
infections than those without Fg-binding proteins [38]. Fibrinogen activity (i.e., function) has
been shown to be susceptible to oxidative species [39], providing further motivation for its use
in studies elucidating NO’s effect on bacterial adhesion.
Prior to probing the influence of NO release, the fundamental effect of pre-adsorbed Fg and
BSA on bacterial adhesion was evaluated. Bacterial adhesion to control (i.e., incapable of NO
release) surfaces pre-treated with Fg was compared to controls pre-treated with BSA under the
same conditions to differentiate between specific Fg-mediated interactions and general protein-
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protein interactions. As shown in Figure 2, pre-treatment of the PVC surface with BSA resulted
in significantly reduced bacterial adhesion for each of the three species tested. Such reduction
is consistent with the observations of others [40] and may be the result of decreased surface
hydrophobicity in the presence of the BSA layer [41]. Indeed, the water contact angle for bare
PVC and BSA-coated surfaces was 78.6 ± 4.0° to 35.4 ± 3.1°, respectively, indicating a
decrease in surface hydrophobicity upon BSA modification.
In contrast, the extent of bacterial adhesion was greater to substrates with pre-adsorbed Fg
compared to substrates without protein or those modified with BSA (Figure 2). The most
significant increase was observed in the case of S. aureus, where adhesion to Fg-coated
substrates was more than 5 times that of uncoated controls. Baumgartner et al. reported similar
results for S. aureus adhesion to polyurethane surfaces with pre-adsorbed Fg [42]. In a similar
study, S. epidermidis adhesion to control catheters without pre-adsorbed functional Fg was
approximately half that observed at Fg-coated catheters [43]. Our data also indicate that the
presence of adsorbed Fg increases S. epidermidis adhesion by ~26%, substantially less than
the >5-fold increase observed with S. aureus. Nevertheless, the Fg-mediated increase in S.
epidermidis adhesion proved significant (p < 0.05). The adhesion of E. coli to Fg-treated PVC-
coated xerogels was ~83% greater than control PVC-coated xerogels. Collectively, the data
indicate that the increase in bacterial adhesion is the result of specific Fg-mediated interactions
between the bacterial cells and the substrate [44] and not non-specific interactions between
bacterial cells and the protein layer as adhesion was reduced in the presence of BSA and
enhanced in the presence of Fg. The increased bacterial adhesion at Fg pre-treated substrates
was also not the result of greater hydrophobic interactions, since the water contact angle was
reduced from 78.6 ± 4.0° to 50.0 ± 4.5° for bare PVC and Fg-coated substrates, respectively,
after Fg treatment. Increased bacterial adhesion due to specific bacteria-Fg interactions is
consistent with the observations of others [31–33,40].
Inhibition of bacterial adhesion via NO release
While previous studies have established that NO release reduces bacterial adhesion in buffer
solutions [25–28,45], none have directly examined the antibacterial efficacy of NO-releasing
surfaces in the presence of an adhesion-promoting protein conditioning layer. A primary
advantage of active release antibacterial coatings is the ability to reduce bacterial adhesion in
the presence of adsorbed proteins [9,10]. The studies described below were thus conducted to
assess the ability of NO release to prevent bacterial adhesion in the presence of an adhesion-
promoting protein layer.
Similar to previous work with P. aeruginosa [28], an inverse relationship between NO release
and bacterial adhesion was observed for the three bacterial species examined herein (Figure 3
and Figure 4). Fluxes of NO between 10 and 30 pmol cm−2 s−1 resulted in statistically
significant decreases in bacterial adhesion (Table 1). At a NO flux of 30 pmol cm−2 s−1 (the
greatest flux examined), adhesion of S. aureus and E. coli was decreased by 96 and 88%,
respectively, relative to bacterial adhesion to Fg-treated xerogel controls. Plots of relative
bacterial adhesion versus NO flux for S. aureus and E. coli demonstrated a negative correlation
between NO release and bacterial adhesion (Figure 3). Overall, the NO release reduced S.
aureus adhesion to a greater extent than E. coli adhesion. S. aureus was also more susceptible
to the effects of NO release at lower fluxes. For example, the adhesion of S. aureus was reduced
by ~40% at a NO flux of 10.6 pmol cm−2 s−1 (relative to controls) while E. coli adhesion was
reduced by only ~20% (versus controls) at an identical NO flux. Comparison of the
effectiveness of NO release at reducing adhesion by the different bacterial species was
accomplished by relating the slopes from the linear regression equations derived from the plots
of relative adhesion versus NO flux. For S. aureus and E. coli adhesion, the slope of the linear
regression was −3.3 ± 0.3 and −3.0 ± 0.5% bacterial surface coverage per pmol NO cm−2
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s−1, respectively. Despite greater overall surface coverage for S. aureus, the decrease in relative
adhesion with increasing NO flux was statistically equivalent for both S. aureus and E. coli,
indicating that the marginal effect of increasingly higher NO fluxes is similar for both species.
The antibacterial efficacy of NO against S. epidermidis adhesion to Fg-treated xerogels was
less than that observed for S. aureus and E. coli. Although the absolute decrease in S.
epidermidis adhesion over the range of NO fluxes studied was not as large, greater NO fluxes
(23 and 30 pmol cm−2 s−1) maintained a stronger inhibitory effect on adhesion (Table 1). Using
the data points at all five NO fluxes to generate a linear regression equation for S.
epidermidis, a slope of −1.4 ± 0.4% bacterial surface coverage per pmol NO cm−2 s−1 was
determined. A second linear regression equation determined using only the adhesion data for
the three highest fluxes, the region where adhesion appears to be more strongly influenced by
increasing NO flux, revealed a slope of −3.1 ± 0.6% bacterial surface coverage per pmol NO
cm−2 s−1. The slope from the abbreviated data set was statistically similar to the slopes from
the E. coli and S. aureus adhesion plots, supporting the hypothesis that a strong, negative
correlation exists between the relative adhesion of S. epidermidis and NO flux, but only at
elevated NO fluxes. It is thus evident that fluxes of NO greater than a threshold value of ~18
pmol cm−2 s−1 are necessary to inhibit S. epidermidis adhesion to the same extent as S.
aureus and E. coli. The uniformity of the linear regression slopes and the ability to inhibit the
adhesion of both gram-positive and gram-negative bacteria suggests a general mode of NO’s
anti-adhesion activity, albeit requiring different NO fluxes for different species. Studies of
additional bacterial species may help to further elucidate this hypothesis. Importantly, our data
suggest that polymeric NO release is an effective strategy for reducing the Fg-mediated
adhesion of both gram-positive (e.g., S. aureus, S. epidermidis) and gram-negative (e.g., E.
coli) bacteria despite the differences in membrane properties and adhesive proteins that
distinguish these classifications of bacteria [46].
To exclude the possibility that variations in bacterial adhesion are the result of differences in
the amount of adsorbed Fg at control and NO-releasing surfaces, a fluorescently-labeled protein
adsorption experiment was used to quantify Fg adhesion. Congruent with the procedure for
testing bacterial adhesion, PVC-coated control and NO-releasing xerogels were immersed in
PBS at 37 °C for 90 min, then transferred to a 20 µg/mL solution of Fg. The Fg solution
consisted of 90% (v/v) unlabeled human Fg and 10% Alexa Fluor 488-modified human Fg.
Following 90 min immersion in the Fg solution, the substrates were transferred to a 5 wt%
SDS solution [36] and incubated for 90 min at 37 °C to remove the protein from the substrate.
Fluorescence intensity measurements revealed no significant difference between samples in
which control and NO-releasing substrates had been incubated (measured fluorescence
intensities of 1.6 ± 0.5 and 1.4 ± 0.1 AU for control and NO-releasing samples, respectively;
p > 0.05). The data indicate that the observed reduction in bacterial adhesion must be attributed
solely to the surface flux of NO. Whether the xerogel-derived NO alters the structure or function
of adsorbed Fg requires more study. Recent work in our laboratory has focused on elucidating
NO’s influence on fibrinogen function in solution, particularly its polymerization to fibrin
[47]. In both nitrosoglutathione (a NO donor) and control (i.e., glutathione) solutions, fibrin
polymerization was impaired to the same extent, suggesting that NO itself does not directly
interfere with Fg function.
Conclusions
Nitric oxide release from xerogel polymer surfaces reduced S. aureus, S. epidermidis, and E.
coli adhesion in the presence of pre-adsorbed Fg, a plasma protein known to mediate implant-
associated infection. Reduction of S. aureus and E. coli adhesion correlated strongly with NO
surface flux in the range of 0 to 30 pmol cm−2 s−1. A NO surface flux of 30 pmol cm−2 s−1
reduced the relative surface coverage of S. aureus and E. coli by 96 and 88%, respectively.
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The relationship between bacterial adhesion and NO flux for E. coli and S. aureus fit a linear
model with a common rate of change (approximately −3% relative surface coverage per pmol
cm−2 s−1 of NO flux). While S. epidermidis adhesion did not correlate strongly with NO flux
throughout the range of 0 to 30 pmol cm−2 s−1, a strong correlation for S. epidermidis was
observed in the range of 18 to 30 pmol cm−2 s−1. These data suggest that NO release is more
effective at inhibiting the adhesion of S. aureus and E. coli than S. epidermidis in the presence
of pre-adsorbed fibrinogen.
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Nitric oxide release profiles for 10 (A), 20 (B), 30 (C), and 40% (D) AHAP3 xerogels (v/v,
balance BTMOS) from t = 0 to t = 8 h. Inset: NO release from t = 3 to t = 4.5 h, corresponding
to the period during which xerogels were incubated in bacterial suspensions.
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Effect of pre-adsorbed fibrinogen and BSA on S. aureus, S. epidermidis, and E. coli adhesion
to PVC-coated control 40% AHAP3 xerogels (v/v, balance BTMOS) at 37 °C. For each
bacterial species, the difference in adhesion between substrates with no pre-adsorbed protein
and both fibrinogen and BSA-coated substrates was significant (p < 0.05).
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Influence of NO surface flux on S. aureus (A), E. coli (B), and S. epidermidis (C) adhesion to
PVC-coated NO-releasing xerogels.
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Representative phase contrast images of E. coli (A, D); S. aureus (B, E); and S. epidermidis
(C, F) adhesion to fibrinogen-coated control (A, B, C) and NO-releasing (D, E, F) 40% AHAP3
xerogels (v/v, balance BTMOS) at 37 °C. Cells are white. Images are 215 × 270 µm2.
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